Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial ...

Be Biopharma, Inc. ("Be Bio"), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced that an abstract relating to its BCM platform has been accepted for oral ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their ...

Q3 2024 Earnings Call Transcript November 4, 2024 Eve Holding, Inc. beats earnings expectations. Reported EPS is $-0.12016, expectations were $-0.14. Operator: Good day and welcome to the Eve Air ...